Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • GLP-1 (9-36) Amide: The Benchmark GLP-1 Receptor Antagoni...

    2026-02-12

    GLP-1 (9-36) Amide: The Benchmark GLP-1 Receptor Antagonist Peptide

    Principle and Experimental Setup: The Role of GLP-1 (9-36) Amide in GLP-1 Receptor Pathway Studies

    GLP-1 (9-36) amide is a rigorously characterized human GLP-1 receptor antagonist peptide, distinguished by its ability to selectively inhibit GLP-1 receptor (GLP-1R) signaling without off-target effects at related G protein–coupled receptors (GPCRs). As detailed in the pivotal high-throughput FRET cAMP assay study, precise modulation of GLP-1R is essential for unraveling the nuanced interplay between incretin hormones, insulin secretion, and metabolic regulation. This peptide is especially critical for metabolic regulation studies and type 2 diabetes research, where dissecting GLP-1 receptor pathway dynamics can reveal targets for next-generation therapeutics.

    Supplied as a white, lyophilized solid (MW 3089.44 Da, C140H214N36O43), GLP-1 (9-36) amide from APExBIO is validated to 100% purity (HPLC, MS) and comes with a comprehensive Certificate of Analysis. Notably, its insolubility in DMSO, ethanol, and water necessitates specialized handling, while its desiccated storage at -20°C ensures optimal stability. The peptide's unique pharmacological profile has made it the gold standard for GLP-1 receptor signaling research, offering unmatched selectivity as a peptide antagonist for receptor studies.

    Step-by-Step Experimental Workflow: Optimizing GLP-1 (9-36) Amide Use

    1. Peptide Preparation and Handling

    • Receiving and Storage: Upon arrival, verify that GLP-1 (9-36) amide is shipped on blue ice (small molecule) or dry ice (modified nucleotide). Immediately transfer to a desiccated environment at -20°C. Avoid repeated freeze-thaw cycles.
    • Resuspension: Due to its insolubility in common solvents (DMSO, ethanol, water), dissolve the peptide in 0.1% trifluoroacetic acid (TFA) or a buffer containing mild chaotropes (e.g., 6M guanidine-HCl or 8M urea), ensuring gentle agitation. Filter sterilize if cell culture application is required. Use the solution promptly, as long-term storage in solution is not recommended.

    2. Cell-Based GLP-1 Receptor Antagonism Assays

    • Cell Model Selection: Use GLP-1R-expressing cell lines (e.g., INS-1 832/13, HEK293-GLP-1R) for optimal responsiveness. Confirm receptor expression by qPCR or immunoblot prior to assay initiation.
    • Treatment Regimen: Pre-incubate cells with GLP-1 (9-36) amide at concentrations ranging from 10 nM to 1 μM for 15–30 minutes prior to agonist (e.g., GLP-1, exendin-4) stimulation. Adjust antagonist concentration based on pilot inhibition curves.
    • Functional Readouts: Quantify cAMP accumulation via FRET-based biosensors, ELISA, or HTRF kits. Assess insulin secretion modulation in pancreatic beta cells using standardized glucose-stimulation protocols.

    3. Advanced Applications: Pathway Dissection and In Vivo Validation

    • Pathway Specificity: Combine GLP-1 (9-36) amide with alternative receptor agonists or antagonists to examine cross-reactivity and specificity, as highlighted in the referenced FRET study. This allows for the exploration of nonconventional agonist/antagonist interactions and the dissection of metabolic regulation circuits.
    • In Vivo Use: For animal studies, ensure appropriate vehicle formulation (e.g., dilute TFA-neutralized peptide in saline for injection). Monitor blood glucose, insulin, and cAMP levels to quantify GLP-1R antagonism effects in metabolic disease models.

    For further protocol refinement and troubleshooting, the article "GLP-1 (9-36) Amide: The Benchmark GLP-1 Receptor Antagoni..." complements this workflow with specialized troubleshooting insights and nuanced protocol adjustments for incretin hormone signaling research.

    Advanced Applications and Comparative Advantages

    1. Specificity and Benchmarking

    GLP-1 (9-36) amide’s specificity as a human GLP-1 receptor antagonist is supported by studies demonstrating minimal off-target effects at glucagon or GIP receptors, a limitation seen with some small-molecule antagonists. In comparative FRET-based cAMP assays (Chepurny et al., 2019), GLP-1 (9-36) amide achieved >90% inhibition of GLP-1-induced cAMP signal at submicromolar concentrations, while not suppressing glucagon-mediated pathways, thus outperforming broader-acting antagonists.

    Compared to Exendin(9–39), another GLP-1R antagonist, GLP-1 (9-36) amide offers a distinct pharmacokinetic profile and is less likely to induce receptor internalization, making it ideal for chronic pathway dissection in metabolic studies.

    2. Integration into Complex Metabolic Regulation Studies

    The peptide is frequently deployed in type 2 diabetes research to parse out the direct effects of GLP-1R antagonism on insulin secretion modulation. This is crucial for benchmarking incretin hormone signaling interventions in in vitro and in vivo metabolic regulation studies, where GLP-1 receptor pathway modulation can impact both hepatic and pancreatic function.

    For researchers employing hybrid or triagonist peptides, as introduced in the reference study, GLP-1 (9-36) amide serves as the definitive negative control for isolating GLP-1-specific effects in the presence of multi-receptor agonists.

    To extend your experimental versatility, the article "GLP-1 (9-36) Amide: Optimizing GLP-1 Receptor Antagonist ..." provides advanced use-case scenarios and comparative data, complementing the approaches discussed here.

    Troubleshooting and Optimization Tips

    • Solubility Challenges: If issues persist with peptide dissolution, incrementally warm the solution (up to 37°C) and extend agitation time. Avoid sonication, which may degrade peptide integrity.
    • Handling Instability: Prepare aliquots sized for single-use experiments to prevent freeze-thaw cycles and limit degradation. If precipitation occurs after resuspension, centrifuge and use only the clear supernatant.
    • Assay Interference: Confirm absence of vehicle/control effects by running parallel buffer-treated controls. Ensure the pH of the final solution matches physiological conditions to avoid cell toxicity.
    • Dose Optimization: Conduct preliminary dose-response curves. For cAMP-based FRET assays, 100–500 nM typically achieves maximal antagonism, but pilot titration is recommended due to cell line variability.
    • Batch Verification: Use the provided Certificate of Analysis and Material Safety Data Sheet from APExBIO to validate batch purity and peptide identity.

    For scenario-driven troubleshooting and evidence-based protocol adjustments, "GLP-1 (9-36) amide: Reliable Solutions for GLP-1 Receptor..." offers practical insights into assay optimization and data interpretation, effectively extending the troubleshooting strategies outlined here.

    Future Outlook: Next-Generation GLP-1 Receptor Pathway Research

    As metabolic research advances, the need for highly selective and reliable GLP-1 receptor antagonists like GLP-1 (9-36) amide is set to grow. Its pivotal role in dissecting incretin hormone signaling supports the development of dual and triagonist therapeutic strategies targeting complex GPCR networks, as highlighted by innovations in the Chepurny et al. (2019) study. With new peptide constructs and hybrid agonists under investigation for metabolic disease and obesity, robust negative controls—such as GLP-1 (9-36) amide—will remain essential for mechanistic clarity and drug candidate validation.

    For researchers seeking a trusted, high-purity reagent, GLP-1 (9-36) amide from APExBIO is the gold standard. Its rigorous quality control, detailed documentation, and proven performance across type 2 diabetes research and metabolic regulation studies make it the preferred choice for bench scientists worldwide.

    Conclusion

    GLP-1 (9-36) amide is more than just a GLP-1 receptor antagonist peptide—it is a cornerstone reagent for GLP-1 receptor signaling research, enabling precise interrogation of metabolic pathways and incretin hormone dynamics. By integrating robust experimental workflows, advanced troubleshooting, and comparative insights (see also "GLP-1 (9-36) amide: Antagonist Peptide for GLP-1 Receptor...", which provides atomic-level mechanism details), researchers can unlock reproducible, high-impact findings in the quest to understand and treat metabolic disorders.